PPARγ is well known as a regulator of insulin sensitivity and TZD drugs ameliorate insulin resistance by reducing plasma glucose and they improve the lipidemic profile in type 2 diabetes (T2D) and in obese subjects without diabetes [384]. This evidence concerns the gene INS and type 2 diabetes mellitus.